Bacil Pharma Limited (BOM:524516)
India
· Delayed Price · Currency is INR 50.00
+0.05 (0.10%)
At close: Mar 9, 2026
Bacil Pharma Balance Sheet
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2020 - 2016 |
| Cash & Equivalents | - | 28.57 | 0.41 | 0.29 | 2.3 | 0.99 | Upgrade
|
| Trading Asset Securities | - | - | - | 1.91 | 0.76 | 1.39 | Upgrade
|
| Cash & Short-Term Investments | 15.94 | 28.57 | 0.41 | 2.2 | 3.06 | 2.38 | Upgrade
|
| Cash Growth | 1256.43% | 6788.85% | -81.12% | -28.26% | 28.71% | 7.33% | Upgrade
|
| Other Receivables | - | - | - | - | - | 0 | Upgrade
|
| Receivables | - | - | - | - | - | 0 | Upgrade
|
| Other Current Assets | - | 0.5 | 0.11 | 0.09 | 0.1 | 0.64 | Upgrade
|
| Total Current Assets | - | 29.07 | 0.52 | 2.29 | 3.16 | 3.02 | Upgrade
|
| Property, Plant & Equipment | - | - | 0.06 | 0.08 | 0.11 | 0.15 | Upgrade
|
| Long-Term Investments | - | 213.57 | 6.11 | 2.36 | 2.36 | 2.36 | Upgrade
|
| Long-Term Deferred Tax Assets | - | 0.54 | 0.56 | 1.17 | 1.08 | 1.08 | Upgrade
|
| Other Long-Term Assets | - | 0 | - | 0 | -0 | 25 | Upgrade
|
| Total Assets | - | 256 | 13.26 | 11.27 | 12.72 | 40.88 | Upgrade
|
| Accounts Payable | - | 0.04 | 0.04 | 0 | 0.11 | 0.11 | Upgrade
|
| Accrued Expenses | - | - | 0.09 | 0.06 | 0.02 | 0.09 | Upgrade
|
| Short-Term Debt | - | 1.64 | 0.98 | 0.21 | 0.33 | 1.76 | Upgrade
|
| Current Unearned Revenue | - | - | - | - | - | 25 | Upgrade
|
| Other Current Liabilities | - | 0.01 | 0.02 | 0.01 | 0.02 | 0.01 | Upgrade
|
| Total Current Liabilities | - | 1.69 | 1.13 | 0.28 | 0.47 | 26.97 | Upgrade
|
| Other Long-Term Liabilities | - | 0 | - | 0 | - | - | Upgrade
|
| Total Liabilities | - | 1.69 | 1.13 | 0.28 | 0.47 | 26.97 | Upgrade
|
| Common Stock | - | 139.7 | 58.9 | 58.9 | 58.9 | 58.9 | Upgrade
|
| Retained Earnings | - | 114.61 | -53.14 | -54.28 | -53.03 | -51.36 | Upgrade
|
| Comprehensive Income & Other | - | - | 6.37 | 6.37 | 6.37 | 6.37 | Upgrade
|
| Shareholders' Equity | 263.5 | 254.31 | 12.13 | 10.99 | 12.24 | 13.91 | Upgrade
|
| Total Liabilities & Equity | - | 256 | 13.26 | 11.27 | 12.72 | 40.88 | Upgrade
|
| Total Debt | - | 1.64 | 0.98 | 0.21 | 0.33 | 1.76 | Upgrade
|
| Net Cash (Debt) | 15.94 | 26.93 | -0.57 | 1.99 | 2.73 | 0.62 | Upgrade
|
| Net Cash Growth | - | - | - | -27.11% | 338.69% | 17.88% | Upgrade
|
| Net Cash Per Share | 1.29 | 4.27 | -0.10 | 0.33 | 0.46 | 0.11 | Upgrade
|
| Filing Date Shares Outstanding | 13.07 | 14.35 | 5.89 | 5.89 | 5.89 | 5.89 | Upgrade
|
| Total Common Shares Outstanding | 13.07 | 14.35 | 5.89 | 5.89 | 5.89 | 5.89 | Upgrade
|
| Working Capital | - | 27.39 | -0.61 | 2.01 | 2.69 | -23.95 | Upgrade
|
| Book Value Per Share | 19.09 | 17.72 | 2.06 | 1.87 | 2.08 | 2.36 | Upgrade
|
| Tangible Book Value | 263.5 | 254.31 | 12.13 | 10.99 | 12.24 | 13.91 | Upgrade
|
| Tangible Book Value Per Share | 19.09 | 17.72 | 2.06 | 1.87 | 2.08 | 2.36 | Upgrade
|
| Machinery | - | 0.59 | 0.55 | 0.59 | 0.59 | 0.59 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.